✦ LIBER ✦

Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receiving 14 days of therapy

✍ Scribed by Eric Lawitz; Eliot Godofsky; Regine Rouzier; Thomas Marbury; Tuan Nguyen; June Ke; MeiMei Huang; Jens Praestgaard; Denise Serra; Thomas G. Evans

Book ID: 113458482
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 620 KB
Volume: 89
Category: Article
ISSN: 0166-3542
DOI: 10.1016/j.antiviral.2011.01.003

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

1045 SAFETY AND ANTIVIRAL EFFICACY OF 14

1045 SAFETY AND ANTIVIRAL EFFICACY OF 14 DAYS OF THE CYCOPHILIN INHIBITOR NIM811 IN COMBINATION WITH PEGYLATED INTERFERON α2a IN RELAPSED GENOTYPE 1 HCV INFECTED PATIENTS

✍ Lawitz, E.; Rouzier, R.; Nguyen, T.; Huang, M.; Ke, J.; Praestgaard, J.; Serra, 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 91 KB

2013 ANTIVIRAL ACTIVITY, PHARMACOKINETIC

2013 ANTIVIRAL ACTIVITY, PHARMACOKINETICS AND SAFETY OF IDX184 IN COMBINATION WITH PEGYLATED INTERFERON (PEGIFN) AND RIBAVIRIN (RBV) IN TREATMENT-NAIVE HCV GENOTYPE 1-INFECTED SUBJECTS

✍ Lalezari, J.; Poordad, F.; Mehra, P.; Nguyen, T.; Dejesus, E.; Godofsky, E.; Pat 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 54 KB

1052 ANTIVIRAL ACTIVITY OF FILIBUVIR IN

1052 ANTIVIRAL ACTIVITY OF FILIBUVIR IN COMBINATION WITH PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN FOR 28 DAYS IN TREATMENT NAIVE PATIENTS CHRONICALLY INFECTED WITH HCV GENOTYPE 1

✍ Jacobson, I.; Pockros, P.; Lalezari, J.; Lawitz, E.; Rodriguez-Torres, M.; DeJes 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 70 KB

143 EFFICACY AND SAFETY OF INCREASING DO

143 EFFICACY AND SAFETY OF INCREASING DOSES OF THE CYCLOPHILIN INHIBITOR DEBIO 025 IN COMBINATION WITH PEGYLATED INTERFERON ALPHA-2A IN TREATMENT NAIVE CHRONIC HCV PATIENTS

✍ R. Flisiak; S.V. Feinman; M. Jablkowski; A. Horban; W. Kryczka; W. Halota; J.E. 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 61 KB

95 EFFICACY AND SAFETY OF THE CYCLOPHILI

95 EFFICACY AND SAFETY OF THE CYCLOPHILIN INHIBITOR DEBIO 025 IN COMBINATION WITH PEGYLATED INTERFERON ALPHA-2A AND RIBAVIRIN IN PREVIOUSLY NULL-RESPONDER GENOTYPE 1 HCV PATIENTS

✍ D.R. Nelson; R.H. Ghalib; M. Sulkowski; E. Schiff; V. Rustgi; P.J. Pockros; C. W 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 51 KB